BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

...CFO. Taylor was previously interim CFO at Aetion Inc. and president and CFO at Tyme Inc. (NASDAQ:TYME). OncoMyx...
BioCentury | Oct 17, 2020
Product Development

How the PanCAN master protocol could promote innovation in pancreatic cancer

...will start by testing SM-88 (racemetyrosine) from Tyme Inc....
...lacked a strong patient community. Having brought Tyme...
...on, such as a quick readout for Tyme’s...
BioCentury | Aug 27, 2020
Product Development

COVID-19 Quick Takes: FDA authorizes 15-minute, $5 antigen test from Abbott; plus  updates from IDSA, CEPI, Novavax, VBI, Verndari, AZ, Fluidigm, Tyme

...tests in reserve (see “NIH, HHS Fast-tracking Point-of-care”).Tyme...
...trial of bile acid therapyTyme Technologies Inc. (NASDAQ:TYME...
...Center to start a placebo-controlled trial of TYME-19...
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

...operating and chief commercial officer, a new position. She was COO at Tyme Technologies Inc. (NASDAQ:TYME...
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...of Poxel S.A. (Euronext:POXEL) and Artios Pharma Ltd. (Cambridge, U.K.). Cancer company Tyme Technologies Inc. (NASDAQ:TYME...
BioCentury | Jan 25, 2019
Clinical News

Tyme shares tumble after pancreatic cancer data

...Tyme Technologies Inc. (NASDAQ:TYME) lost $1.32 (35%) to $2.41 on Jan. 18 after the company reported...
...American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco. Tyme Technologies Inc. (NASDAQ:TYME...
...II data Milestone: Complete Phase II (12/2019) Chris Lieu Oral SM-88, SM88, SM-88, TYME-88 American Society of Clinical Oncology ASCO Tyme...
BioCentury | Oct 15, 2018
Company News

Management tracks: Rhythm, Redpin

...EVP of Medical Devices Robert Ford to president and COO. Cancer company Tyme Technologies Inc. (NASDAQ:TYME...
BioCentury | Sep 29, 2017
Clinical News

Tyme reports Phase I data of SM-88 in metastatic cancer

...Tyme Technologies Inc. (NASDAQ:TYME) reported data from an open-label Phase I trial in 30 patients with...
...an open-label Phase I trial in 30 patients with progressive metastatic cancer showing that SM-88 (TYME-88...
...II trial in pancreatic cancer. Tyme Technologies Inc. (NASDAQ:TYME), New York, N.Y. Product: SM-88 ( TYME-88...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...Greg Anglum to SVP and CFO from chief accounting officer. Cancer play Tyme Technologies Inc. (NASDAQ:TYME...
BioCentury | Jun 23, 2017
Clinical News

Tyme reports Phase I data for TYME-88 in pancreatic cancer

...evaluable patients with refractory pancreatic cancer in an open-label, U.S. Phase I trial showing that TYME-88...
...of TYME-88 to treat refractory pancreatic cancer. Tyme Technologies Inc. (OTCQB:TYMI), New York, N.Y. Product: TYME-88...
...Endpoint: NA Status: Phase I data Milestone: Start Phase II (1Q18) Alex Himes SM-88 SM88 TYME-88 American Society of Clinical Oncology ASCO Tyme...
Items per page:
1 - 10 of 16
BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

...CFO. Taylor was previously interim CFO at Aetion Inc. and president and CFO at Tyme Inc. (NASDAQ:TYME). OncoMyx...
BioCentury | Oct 17, 2020
Product Development

How the PanCAN master protocol could promote innovation in pancreatic cancer

...will start by testing SM-88 (racemetyrosine) from Tyme Inc....
...lacked a strong patient community. Having brought Tyme...
...on, such as a quick readout for Tyme’s...
BioCentury | Aug 27, 2020
Product Development

COVID-19 Quick Takes: FDA authorizes 15-minute, $5 antigen test from Abbott; plus  updates from IDSA, CEPI, Novavax, VBI, Verndari, AZ, Fluidigm, Tyme

...tests in reserve (see “NIH, HHS Fast-tracking Point-of-care”).Tyme...
...trial of bile acid therapyTyme Technologies Inc. (NASDAQ:TYME...
...Center to start a placebo-controlled trial of TYME-19...
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

...operating and chief commercial officer, a new position. She was COO at Tyme Technologies Inc. (NASDAQ:TYME...
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...of Poxel S.A. (Euronext:POXEL) and Artios Pharma Ltd. (Cambridge, U.K.). Cancer company Tyme Technologies Inc. (NASDAQ:TYME...
BioCentury | Jan 25, 2019
Clinical News

Tyme shares tumble after pancreatic cancer data

...Tyme Technologies Inc. (NASDAQ:TYME) lost $1.32 (35%) to $2.41 on Jan. 18 after the company reported...
...American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco. Tyme Technologies Inc. (NASDAQ:TYME...
...II data Milestone: Complete Phase II (12/2019) Chris Lieu Oral SM-88, SM88, SM-88, TYME-88 American Society of Clinical Oncology ASCO Tyme...
BioCentury | Oct 15, 2018
Company News

Management tracks: Rhythm, Redpin

...EVP of Medical Devices Robert Ford to president and COO. Cancer company Tyme Technologies Inc. (NASDAQ:TYME...
BioCentury | Sep 29, 2017
Clinical News

Tyme reports Phase I data of SM-88 in metastatic cancer

...Tyme Technologies Inc. (NASDAQ:TYME) reported data from an open-label Phase I trial in 30 patients with...
...an open-label Phase I trial in 30 patients with progressive metastatic cancer showing that SM-88 (TYME-88...
...II trial in pancreatic cancer. Tyme Technologies Inc. (NASDAQ:TYME), New York, N.Y. Product: SM-88 ( TYME-88...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...Greg Anglum to SVP and CFO from chief accounting officer. Cancer play Tyme Technologies Inc. (NASDAQ:TYME...
BioCentury | Jun 23, 2017
Clinical News

Tyme reports Phase I data for TYME-88 in pancreatic cancer

...evaluable patients with refractory pancreatic cancer in an open-label, U.S. Phase I trial showing that TYME-88...
...of TYME-88 to treat refractory pancreatic cancer. Tyme Technologies Inc. (OTCQB:TYMI), New York, N.Y. Product: TYME-88...
...Endpoint: NA Status: Phase I data Milestone: Start Phase II (1Q18) Alex Himes SM-88 SM88 TYME-88 American Society of Clinical Oncology ASCO Tyme...
Items per page:
1 - 10 of 16